Remove 2015 Remove Government Remove Manufacturing Remove Provider
article thumbnail

The 6-Year Saga Finally Ends: FDA Issues Final Rule Modifying The Intended Use Regulation

FDA Law

FDA has now issued a final rule governing how intended use of a distributed product is to be determined. Thus ends a saga that began with a proposal in 2015 to amend the “intended use” regulation. label use if the manufacturer knew about it. The proposal to delete this provision made sense , because the off?label

article thumbnail

FIFA Cases Hold Lessons for FDA-Regulated Companies – Organizations can be Victims of Their Own Employees’ Criminal Conduct

FDA Law

In its Compliance Guidance for Pharmaceutical Manufacturers , the HHS OIG notes: The OIG recognizes that the implementation of a compliance program may not entirely eliminate improper conduct from the operations of a pharmaceutical manufacturer. Generally speaking, that recognition has limits, however.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gabapentinoids – Gabapentin and Pregabalin: Tasce Bongiovanni, Donovan Maust and Nisha Iyer

GeriPal

By 2015 that number increased to 4% of US adults. Eric: Any other interesting tidbits or facts that we should know as providers about gabapentin or Lyrica dosing or pharmacology? We should be able to trust all the data that comes from our governing board. So that’s kind of how it first came on my radar.

article thumbnail

Aging and Climate Change: Karl Pillemer, Leslie Wharton, & Ruth McDermott-Levy

GeriPal

So if you look at government websites about heat for example, it’s got a line of buttons across the top with affected populations, outdoor workers, athletes and older people are in there. And we have gone from 250 members at the end of 2015 to about 26,000 right now across the United States and a number of chapters that have grown.

article thumbnail

Drug Pricing Reform Gathers Steam (Part 2)

FDA Law

This bill, which addresses numerous areas of the economy, public health, and government regulation, includes Subtitle E, Drug Pricing. The MFP would be established through negotiations between HHS and the manufacturer and would incorporate foreign pricing benchmarks, as further described below. 3, the Elijah E.